ReviewThe Lancet. Oncology2018
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Review in The Lancet. Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 5 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.Frontiers in medicine · 2026Pooled it
- Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.World journal of urology · 2021Pooled it
- Imaging for Metastasis in Prostate Cancer: A Review of the Literature.Frontiers in oncology · 2020Pooled it
- Ablative radiotherapy in castration-resistant prostate cancer.BJU international · 2026Trial
- Phase III Study ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Trial
- Trial
- [The Journal of urology · 2020Trial
- Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.BMC cancer · 2020Trial
- Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.Journal of gastrointestinal cancer · 2025Review
- Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it.Skeletal radiology · 2024Review
- The Lancet Commission on prostate cancer: planning for the surge in cases.Lancet (London, England) · 2024Review
- Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study.Frontiers in oncology · 2024Article
- Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.Cancers · 2023Review
- The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2023Article
- Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion.Current oncology (Toronto, Ont.) · 2023Article
- Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.Therapeutic advances in medical oncology · 2023Review
- Oligometastatic Prostate Cancer: Current Status and Future Challenges.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 12 institutions in 7 countries.
Funding
Abstract
Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.